- Home
- NVO
NVO
Novo Nordisk A/S
as 10-16-2025 3:54pm EST
With roughly one third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (constituting less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
| Founded: | 1923 | Country: | Denmark |
| Employees: | N/A | City: | N/A |
| Market Cap: | 278.0B | IPO Year: | N/A |
| Target Price: | $80.40 | AVG Volume (30 days): | 13.1M |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | Dividend Payout Frequency: | Semi-Annual | |
| EPS: | 3.93 | EPS Growth: | 24.25 |
| 52 Week Low/High: | $45.05 - $119.07 | Next Earning Date: | 11-05-2025 |
| Revenue: | $49,108,936,497 | Revenue Growth: | 20.91% |
| Revenue Growth (this year): | 9.58% | Revenue Growth (next year): | 7.39% |
Latest Novo Nordisk A/S News
NVO Breaking Stock News: Dive into NVO Ticker-Specific Updates for Smart Investing
Motley Fool
20 hours ago
A Deal With Novo Nordisk Sent This Stock 181% Higher Overnight. Is It a Buy Now?
Investor's Business Daily
a day ago
Omeros Catapults 154% On A Surprise $2.1 Billion Deal With Novo Nordisk
Barchart
a day ago
Novo Nordisk Just Signed a Key Drug Deal With Omeros. Is There Any Room Left for OMER Stock to Run?
MT Newswires
a day ago
Sector Update: Health Care Stocks Advance Late Afternoon
MT Newswires
a day ago
Sector Update: Health Care
GuruFocus.com
a day ago
Novo Nordisk Makes $2.1 Billion Rare-Disease Bet After Losing Ground in Obesity Race
MT Newswires
a day ago
Top Midday Gainers
MT Newswires
a day ago
Sector Update: Health Care Stocks Softer in Afternoon Trading
Compare NVO vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "NVO Novo Nordisk A/S - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.